Study #2022-0485
Phase 2 study of combination Tivozanib and Nivolumab in advanced non-clear cell renal cell carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Tivozanib, Nivolumab
Description
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Eric Jonasch
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.